Table 5.
Topical and systemic treatments according to disease severity
| Adult AD | |||||
|---|---|---|---|---|---|
| Mild | Moderate | Severe | p | ||
| n = 79 | n = 71 | n = 534 | |||
| Topical corticosteroids [n (%)] | Never | 1 (1.3) | 2 (2.8) | 8 (1.5) | 0.003 |
| Previous | 58 (73.4) | 41 (57.7) | 276 (51.7) | ||
| On-going | 20 (25.3) | 28 (39.4) | 250 (46.8) | ||
| Topical calcineurin inhibitors | Never | 50 (63.3) | 40 (56.3) | 135 (25.3) | < 0.001 |
| [n (%)] | Previous | 21 (26.6) | 21 (29.6) | 287 (53.7) | |
| On-going | 8 (10.1) | 10 (14.1) | 112 (21) | ||
| Systemic corticosteroids [n (%)] | Never | 26 (32.9) | 20 (28.2) | 80 (15) | < 0.001 |
| Previous | 50 (63.3) | 48 (67.6) | 404 (75.7) | ||
| On-going | 3 (3.8) | 3 (4.2) | 50 (9.4) | ||
| Systemic antihistamines [n (%)] | Never | 12 (15.2) | 13 (18.3) | 30 (5.6) | < 0.001 |
| Previous | 52 (65.8) | 43 (60.6) | 360 (67.4) | ||
| On-going | 15 (19) | 15 (21.1) | 144 (27) | ||
| n = 79 | n = 71 | n = 531 | |||
| Puva/uva/uvbnb [n (%)] | Never | 65 (82.3) | 59 (83.1) | 297 (55.9) | < 0.001 |
| Previous | 11 (13.9) | 10 (14.1) | 218 (41.1) | ||
| On-going | 3 (3.8) | 2 (2.8) | 16 (3) | ||
| Cyclosporine A [n (%)] | Never | 49 (62) | 46 (64.8) | 149 (27.9) | < 0.001 |
| Previous | 27 (34.2) | 18 (25.4) | 329 (61.6) | ||
| On-going | 3 (3.8) | 7 (9.9) | 56 (10.5) | ||
| Metotrexate [n (%)] | Never | 77 (97.5) | 67 (94.4) | 475 (89) | 0.106 |
| Previous | 2 (2.5) | 4 (5.6) | 52 (9.7) | ||
| On-going | 0 (0) | 0 (0) | 7 (1.3) | ||
| Azathioprine [n (%)] | Never | 79 (100) | 69 (97.2) | 510 (95.5) | 0.386 |
| Previous | 0 (0) | 2 (2.8) | 22 (4.1) | ||
| On-going | 0 (0) | 0 (0) | 2 (0.4) | ||
|
Mycophenolate mofetil/sodium [n (%)] |
Never | 79 (100) | 71 (100) | 533 (99.8) | 0.386 |
| Previous | 0 (0) | 0 (0) | 1 (0.2) | ||
Fisher exact test